# coding=utf-8

document = """
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">30518562</PMID>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1091-6490</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2018</Year>
              <Month>Dec</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
          <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Fenestrations control resting-state block of a voltage-gated sodium channel.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">201814928</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1814928115</ELocationID>
        <Abstract>
          <AbstractText>Potency of drug action is usually determined by binding to a specific receptor site on target proteins. In contrast to this conventional paradigm, we show here that potency of local anesthetics (LAs) and antiarrhythmic drugs (AADs) that block sodium channels is controlled by fenestrations that allow drug access to the receptor site directly from the membrane phase. Voltage-gated sodium channels initiate action potentials in nerve and cardiac muscle, where their hyperactivity causes pain and cardiac arrhythmia, respectively. LAs and AADs selectively block sodium channels in rapidly firing nerve and muscle cells to relieve these conditions. The structure of the ancestral bacterial sodium channel Na<sub>V</sub>Ab, which is also blocked by LAs and AADs, revealed fenestrations connecting the lipid phase of the membrane to the central cavity of the pore. We cocrystallized lidocaine and flecainide with Na<sub>v</sub>Ab, which revealed strong drug-dependent electron density in the central cavity of the pore. Mutation of the contact residue T206 greatly reduced drug potency, confirming this site as the receptor for LAs and AADs. Strikingly, mutations of the fenestration cap residue F203 changed fenestration size and had graded effects on resting-state block by flecainide, lidocaine, and benzocaine, the potencies of which were altered from 51- to 2.6-fold in order of their molecular size. These results show that conserved fenestrations in the pores of sodium channels are crucial pharmacologically and determine the level of resting-state block by widely used drugs. Fine-tuning drug access through fenestrations provides an unexpected avenue for structure-based design of ion-channel-blocking drugs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gamal El-Din</LastName>
            <ForeName>Tamer M</ForeName>
            <Initials>TM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lenaeus</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA 98195.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195; nzheng@uw.edu wcatt@uw.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Catterall</LastName>
            <ForeName>William A</ForeName>
            <Initials>WA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, University of Washington, Seattle, WA 98195; nzheng@uw.edu wcatt@uw.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>PDB</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>6MVV</AccessionNumber>
              <AccessionNumber>6MVW</AccessionNumber>
              <AccessionNumber>6MVX</AccessionNumber>
              <AccessionNumber>6MVY</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
        <NlmUniqueID>7505876</NlmUniqueID>
        <ISSNLinking>0027-8424</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">antiarrhythmic drugs</Keyword>
        <Keyword MajorTopicYN="N">fenestration</Keyword>
        <Keyword MajorTopicYN="N">local anesthetics</Keyword>
        <Keyword MajorTopicYN="N">sodium channel</Keyword>
        <Keyword MajorTopicYN="N">voltage-gating</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30518562</ArticleId>
        <ArticleId IdType="pii">1814928115</ArticleId>
        <ArticleId IdType="doi">10.1073/pnas.1814928115</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
"""
